 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Previous Article | Next Article
The Journal of Neuroscience, February 1, 2001, 21(3):823-833
Ultrastructural Localization of the CB1 Cannabinoid Receptor in µ-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus
José J. Rodríguez1, Kenneth Mackie2, and Virginia M. Pickel1 1 Department of Neurology and Neuroscience, Division of Neurobiology, Weill Medical College of Cornell University, New York, New York 10021, and 2 Department of Anesthesiology, University of Washington, Seattle, Washington 98195
Cannabinoids and opioids are widely consumed drugs of abuse that produce motor depression, in part via respective activation of the cannabinoid subtype 1 receptor (CB1R) and the µ-opioid receptor (µOR), in the striatal circuitry originating in the caudate putamen nucleus (CPN). Thus, the CB1R and µOR may show similar targeting in the CPN. To test this hypothesis, we examined the electron microscopic immunocytochemical labeling of CB1R and µOR in CPN patches of rat brain. Of the CB1R-labeled profiles, 34% (588) were dendrites, presumably arising from spiny as well as aspiny-type somata, which also contained CB1R immunoreactivity. In dendrites, CB1R often was localized to nonsynaptic and synaptic plasma membranes, particularly near asymmetric excitatory-type junctions. Almost one-half of the CB1R-labeled dendrites contained µOR immunoreactivity, whereas only 20% of all µOR-labeled dendrites expressed CB1R. Axons and axon terminals as well as abundant glial processes also showed plasmalemmal CB1R and were mainly without µOR immunoreactivity. Many CB1R-labeled axon terminals were small and without recognizable synaptic junctions, but a few also formed asymmetric, or more rarely symmetric, synapses. The CB1R-labeled glial processes were often perivascular or perisynaptic, surrounding asymmetric excitatory-type axospinous synapses. Our results show that in CPN patches CB1R and µOR are targeted strategically to some of the same postsynaptic neurons, which may account for certain similarities in motor function. Furthermore, they also provide evidence that CB1R may play a major role in the modulation of presynaptic transmitter release and glial functions that are unaffected in large part by opioids active at µOR in CPN.
Key words: marijuana; morphine; striatum; striosome; glutamate; glia; ultrastructure
Copyright © 2001 Society for Neuroscience 0270-6474/01/213823-11$05.00/0
This article has been cited by other articles:
Y. Ren, J. Whittard, A. Higuera-Matas, C. V. Morris, and Y. L. Hurd
Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances
J. Neurosci., November 25, 2009; 29(47): 14764 - 14769.
[Abstract] [Full Text] [PDF]
L.-W. Fu and J. C. Longhurst
Electroacupuncture modulates vlPAG release of GABA through presynaptic cannabinoid CB1 receptors
J Appl Physiol, June 1, 2009; 106(6): 1800 - 1809.
[Abstract] [Full Text] [PDF]
M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, and M. Watanabe
Endocannabinoid-Mediated Control of Synaptic Transmission
Physiol Rev, January 1, 2009; 89(1): 309 - 380.
[Abstract] [Full Text] [PDF]
M. Canals and G. Milligan
Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors
J. Biol. Chem., April 25, 2008; 283(17): 11424 - 11434.
[Abstract] [Full Text] [PDF]
I. Freiman, A. Anton, H. Monyer, M. J. Urbanski, and B. Szabo
Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice
J. Physiol., September 15, 2006; 575(3): 789 - 806.
[Abstract] [Full Text] [PDF]
M. R. Domenici, S. C. Azad, G. Marsicano, A. Schierloh, C. T. Wotjak, H.-U. Dodt, W. Zieglgansberger, B. Lutz, and G. Rammes
Cannabinoid Receptor Type 1 Located on Presynaptic Terminals of Principal Neurons in the Forebrain Controls Glutamatergic Synaptic Transmission
J. Neurosci., May 24, 2006; 26(21): 5794 - 5799.
[Abstract] [Full Text] [PDF]
H. H. Yin and D. M. Lovinger
Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling
PNAS, May 23, 2006; 103(21): 8251 - 8256.
[Abstract] [Full Text] [PDF]
C. Borner, V. Hollt, and J. Kraus
Cannabinoid Receptor Type 2 Agonists Induce Transcription of the {micro}-Opioid Receptor Gene in Jurkat T Cells
Mol. Pharmacol., April 1, 2006; 69(4): 1486 - 1491.
[Abstract] [Full Text] [PDF]
T. Aguado, J. Palazuelos, K. Monory, N. Stella, B. Cravatt, B. Lutz, G. Marsicano, Z. Kokaia, M. Guzman, and I. Galve-Roperh
The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells
J. Neurosci., February 1, 2006; 26(5): 1551 - 1561.
[Abstract] [Full Text] [PDF]
M. Andersson, A. Usiello, A. Borgkvist, L. Pozzi, C. Dominguez, A. A. Fienberg, P. Svenningsson, B. B. Fredholm, E. Borrelli, P. Greengard, et al.
Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons
J. Neurosci., September 14, 2005; 25(37): 8432 - 8438.
[Abstract] [Full Text] [PDF]
C. S. Kearn, K. Blake-Palmer, E. Daniel, K. Mackie, and M. Glass
Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk?
Mol. Pharmacol., May 1, 2005; 67(5): 1697 - 1704.
[Abstract] [Full Text] [PDF]
A. Kofalvi, R. J. Rodrigues, C. Ledent, K. Mackie, E. S. Vizi, R. A. Cunha, and B. Sperlagh
Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis
J. Neurosci., March 16, 2005; 25(11): 2874 - 2884.
[Abstract] [Full Text] [PDF]
J. Corchero, J. M. Oliva, C. Garcia-Lecumberri, S. Martin, E. Ambrosio, and J. Manzanares
Repeated administration with {delta}9- tetrahydrocannabinol regulates {micro}-opioid receptor density in the rat brain
J Psychopharmacol, March 1, 2004; 18(1): 54 - 58.
[Abstract] [PDF]
T. M. Brown, J. M. Brotchie, and S. M. Fitzjohn
Cannabinoids Decrease Corticostriatal Synaptic Transmission via an Effect on Glutamate Uptake
J. Neurosci., December 3, 2003; 23(35): 11073 - 11077.
[Abstract] [Full Text] [PDF]
M. Solinas, L. V. Panlilio, K. Antoniou, L. A. Pappas, and S. R. Goldberg
The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 93 - 102.
[Abstract] [Full Text] [PDF]
T. F. FREUND, I. KATONA, and D. PIOMELLI
Role of Endogenous Cannabinoids in Synaptic Signaling
Physiol Rev, July 1, 2003; 83(3): 1017 - 1066.
[Abstract] [Full Text] [PDF]
L. Walter, A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, and N. Stella
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
J. Neurosci., February 15, 2003; 23(4): 1398 - 1405.
[Abstract] [Full Text] [PDF]
E. Molina-Holgado, J. M. Vela, A. Arevalo-Martin, G. Almazan, F. Molina-Holgado, J. Borrell, and C. Guaza
Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling
J. Neurosci., November 15, 2002; 22(22): 9742 - 9753.
[Abstract] [Full Text] [PDF]
A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al.
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202.
[Abstract] [Full Text] [PDF]
L. Walter, A. Franklin, A. Witting, T. Moller, and N. Stella
Astrocytes in Culture Produce Anandamide and Other Acylethanolamides
J. Biol. Chem., May 31, 2002; 277(23): 20869 - 20876.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|